logo
Share SHARE
FONT-SIZE Plus   Neg

CafePress Prices IPO At $19/Share, Above Estimated Range

CafePress Inc, e-commerce platform enabling customers worldwide to create, buy and sell personalized products, announced the pricing of its initial public offering of 4.5 million common at $19.00 per share, above its estimated offering price range.

In an amended regulatory filing with the U.S. Securities and Exchange Commission on March 27, the company had expected to price the initial public offering of 4.5 million common shares between $16 and $18 per share.

The San Mateo, California-based company shares are expected to begin trading on The Nasdaq Global Select Market on March 29, 2012 under the symbol "PRSS."

Of the shares of common stock in the offering, CafePress is offering 2.5 million shares and selling stockholders are offering 2 million shares.

In addition, certain selling stockholders have granted underwriters a 30-day option to buy 675 thousand additional shares to cover over-allotments, if any.

The company intends to use the net proceeds from this offering for general corporate purposes, including working capital and capital expenditures. In addition, the company may use a portion of the net proceeds to acquire or invest in complementary businesses, products or technologies.

Founded in 1999, the company allows people to create their own designs for t-shirts, stickers, coffee mugs and other products, which the company then helps sell to customers.

J.P. Morgan Securities LLC and Jefferies & Company, Inc. are acting as joint book-running managers for the offering. Cowen and Company, LLC, Janney Montgomery Scott LLC and Raymond James & Associates, Inc. are acting as co-managers.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of Credit Suisse Group AG gained around 8 percent in the morning trading in Zurich after the Swiss banking giant raised its group cost savings target, and also confirmed its medium-term 2018 pre-tax income target. It is almost the end of the year. With the exception of a few, many of the biotech stocks, like the following, on which investors had bet big this year have served up only heartbreak. Now, let's take a look at some of the pending clinical trial catalysts of this month, which will make it a December to remember. Fast food major McDonald's is investing in $12,000 espresso machines for all of its U.S. restaurants, with a view to challenge Starbucks and Dunkin' Donuts in the coffee business, Bloomberg reported. Aiming to attract more customers, the company plans to reintroduce its coffee shop McCafe in 2017..
comments powered by Disqus
Follow RTT